razormd

ADA's 68th Scientific Sessions: A New Look at Insulin Therapy

HAW!!...an article bordering on delusional!!!...let's see:

"Generex Biotechnology was also at this week's ADA event and presented convincing results of a 372 day Phase II study comparing Basal and Pre-Prandial Injection vs. Basal Injection and Generex Oral-lyn in Type-1 Diabetics."

...and if I'm not mistaken they have presented the exact same data at the ADA for something like FOUR YEARS now!!!...and what was the total number of patients?...uhhh, twenty or so?...and it was done in that mecca of scientific discovery -- uhhhh -- Ecuador??...and GNBT, of course, has a stellar record of accomplishments to its credit: losses -- massive; growth of stock outstanding -- exponential; probability of further dilution -- 100 per cent...the only ones that'll ever make money off GNBT are management, brokers and shorts!!

Generex Biotech's Oral-lyn Granted Special Access Authorization by Health Canada

...to "bsharvy"...my "source" for my "claims"?...uhhh, GNBT's own published data and a calculator...they aren't claims, just simple scientific facts.